Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolfenamic Acid with Gemcitabine and Radiation in Pancreatic Cancer
NCT02159248Phase 1Withdrawn
- Start
- Mar 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tolfenamic acid in pancreatic cancer (PC). Primary endpoints: Evaluate safety and toxicity at 16 weeks and Maximum Tolerated Dose. Planned start Mar 2014; status: withdrawn.
02
Drugs
tolfenamic acid
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02159248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159248.